

# Competitor Analysis: P. aeruginosa Vaccines and Therapeutics

<https://marketpublishers.com/r/CA98143808CEN.html>

Date: June 2010

Pages: 22

Price: US\$ 230.00 (Single User License)

ID: CA98143808CEN

## Abstracts

### Product description

The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules against infection with Pseudomonas aeruginosa as of June 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Pseudomonas aeruginosa is an opportunistic gram-negative bacteria that lives in soil, water, and even in environments like hot tubs. For most healthy people, this bacteria seldom poses a problem. Pseudomonas aeruginosa is much more dangerous to populations who have weak immune systems, the elderly, and those who have been hospitalized for long periods of time. People with cystic fibrosis and with full-blown AIDS frequently die from infections created by the bacteria. Hospital-acquired pneumonia, particularly ventilator-associated pneumonia, causes considerable morbidity and mortality despite antimicrobial therapy and advances in supportive care. It is the second most frequent nosocomial infection and is the major cause of death among hospital-acquired infections.

At present there is no approved vaccine available for prevention of P. aeruginosa infection. Treatment of P. aeruginosa infection is limited to number of antibiotics. With the advent of biotechnology, a number of experimental vaccines and therapeutic

antibodies are being evaluated in preclinical and clinical R&D. Peptide and small molecule therapeutics are being developed to fight bacterial infections including those caused by *P. aeruginosa*.

The report includes a compilation of currently active projects in development of vaccines, antibodies, peptides and small molecules targeting *Pseudomonas aeruginosa* for prophylaxis and treatment of *P. aeruginosa* infection. In addition, the report lists company-specific R&D pipelines of *P. aeruginosa* Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

## **Index**

*P. aeruginosa* Vaccines

*P. aeruginosa* Antibodies

*P. aeruginosa* Peptides

*P. Aeruginosa* Small Molecules

*P. aeruginosa* R&D Licensing Agreements

Corporate P. aeruginosa Vaccines & Therapeutics R&D Pipelines

About La Merie

### **About Competitor Analysis Series**

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

## I would like to order

Product name: Competitor Analysis: P. aeruginosa Vaccines and Therapeutics

Product link: <https://marketpublishers.com/r/CA98143808CEN.html>

Price: US\$ 230.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA98143808CEN.html>